EMCM recently renewed its partnership with VCC Medical NV to support the production of RenialeĀ® - a personalised treatment for renal cancer.
Online PR News – 28-August-2015 – Nijmegen, the Netherlands – European Medical Contract Manufacturing BV (EMCM) recently renewed its partnership with VCC Medical NV to support the production of RenialeĀ® - a personalised treatment for renal cancer. EMCM supports the production of RenialeĀ® by aseptically processing cancer tissue from the patientās tumour into a biological medicine, which stimulates the immune system to fight against residual cancer cells.
Developed by VCC Medical NV, RenialeĀ® is capable of significantly prolonging a patientās life by helping to prevent metastases after the removal of the kidney or parts thereof. EMCM supports the production of this revolutionary cancer treatment by aseptically processing the tumours at its ISO and GMP accredited cleanroom facilities as per VCC Medical NVās strict requirements.
āChoosing the right partner is of the utmost importance in the sensitive field of personalised medicine manufacturing. We are happy to have contracted EMCM, a well-established and reliable partner capable of meeting our specialised needs. With great confidence we are facing a fruitful future to reach the common aim, which is serving a well-tolerated treatment to patients with a life threatening disease,ā said Dr. Rueggeberg, Delegate of the Supervisory Board of Vaccentis AG, the parent company and sole owner of VCC Medical NV.
About European Medical Contract Manufacturing BV
Forming part of the Leader Biomedical Group (www.leaderbiomedical.com), we have dedicated ourselves to developing our 1,500m2 ISO and GMP accredited clean room facility into a centre of excellence for the contract manufacturing of volatile liquids, high viscous suspensions, and gels for orthopaedic, dental, medical aesthetic, and niche pharmaceutical applications (www.emcm.com).
About VCC Medical NV
VCC Medical NV is dedicated to developing drugs for patients with serious illnesses, focusing on cancer, and is held by Vaccentis AG, ZĆ¼rich, Switzerland (www.vaccentis.ch), as sole owner of the company. VCC Medical NV continues the promising work with the RenialeĀ® medication in the field of evidence-based medicine. The aim of the consolidation is to consistently further develop well-established medicines in the field of autologous patient treatment which is common to both business units. VCC Medical NV wants to contribute to increased chances of finding a cure in the field of chronic and malignant disorders (www.vcc-medical.nl).